Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence

• Status: Completed
• Trial end date: 2013-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety and efficacy of AGN-214868 in patients with idiopathic overactive bladder (IOAB) and urinary incontinence.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan

Criteria

Inclusion Criteria:

• If female, must be of nonreproductive potential

• If male, must agree to use acceptable contraception

• Symptoms of overactive bladder with urinary urgency incontinence

• Inadequate response or limiting side effects with anticholinergics for the treatment of OAB

Exclusion Criteria:

• Overactive bladder caused by neurological condition (eg, spinal cord injury, multiple sclerosis)

• History of bladder surgery

• Treatment with botulinum toxin therapy of any serotype for any non-urological condition within the prior 12 weeks

• Previous treatment with botulinum toxin therapy of any serotype for any urological condition